NCT00690846

Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum

A Multi-Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum (HUM 04-37)

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Wake Forest University Health Sciences · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to see if Humira (adalimumab) is effective and safe in the treatment of pyoderma gangrenosum.

Detailed description

The primary objective of this study is to obtain preliminary data on the safety and efficacy of adalimumab for the treatment of PG. A secondary objective is to study gene expression in PG.

Conditions

• Pyoderma Gangrenosum

Interventions

Type	Name	Description
DRUG	adalimumab	40 mg weekly adalimumab injection.

Timeline

• Start date: 2007-07-01
• Primary completion: 2007-07-01
• Completion: 2007-07-01
• First posted: 2008-06-05
• Last updated: 2019-12-20

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study